This on-demand webinar was originally recorded on June 23, 2025.
The current prescribing information, including Boxed Warnings for ENHERTU (fam-trastuzumab deruxtecan-nxki) can be found at: https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true
This webinar’s objectives are to:
• Improve awareness on the evolution of the HER2 spectrum
• Reinforce understanding of the clinical value of carefully validated assay selection to accurately identify patients with lower expression of HER2
• Highlight key considerations that impact HER2 IHC scoring, interpretation, and reporting
• Address common questions associated with HER2 IHC scoring, interpretation, and validation
Presenters:
Dr Frédérique Penault-Llorca, General Director, Jean Perrin Center
Professor of Pathology, University of Clermont-Ferrand, Clermont-Ferrand, France
Dr Ana Garrido-Castro, Breast Oncologist, Dana-Farber Cancer Institute Assistant Professor, Harvard Medical School, Boston, Massachusetts
Moderated by: Bob McGonnagle, Publisher, CAP TODAY.
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.